Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: Gene Logic Reports Widened Revenue, Narrowed Loss, Contracted R&D in Q1

NEW YORK, April 29 - Gene Logic today reported wider revenue and a narrower first-quarter loss as it racked up more pharma and biotech subscribers.

Revenue for the period ended March 31 rose to $11.8 million from $8.2 million, and net loss narrowed to $7.5 million, or $.28 a share, from $10.6 million, or $.40 per share, one year ago.


R&D spending contracted in the quarter to $14.3 million from $15.7 million in the year-ago period, Gene Logic said. The company's bank account saw a boost, growing to $185 million as of March 31 compared with $128 million as of the same time last year.


For more information, readers may click here. A conference call is scheduled for 10:00 a.m. Eastern time.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.